In consideration for the SARM program license, Pharmacopeia will apply a portion of its medicinal chemistry resources to an unrelated Bristol-Myers Squibb discovery program for up to three years and pay Bristol-Myers Squibb milestone payments associated with submission and approval of a therapeutic product for marketing and a stepped royalty on net sales of therapeutic SARM products, if any, resulting from the SARM development program.
Pharmacopeia will hold a conference call today, October 15, beginning at 8:30 a.m. Eastern Time to discuss this addition to its clinical portfolio. Forward-looking and material information may be discussed on this conference call.
Date: October 15, 2007
Time: 8:30 a.m. EDT
Domestic Callers: (877) 879-6174
International Callers: (719) 325-4810
Confirmation Code: 3655914
Name of Conference: Pharmacopeia
Webcast information can be accessed by visiting http://www.pharmacopeia.com
A replay of the conference call can be accessed by dialing toll-free (888) 203-1112 in the U.S., or (719) 457-0820 outside the U.S. The access code for the replay is 3655914. A replay of the webcast will also be accessible on Pharmacopeia's website on the "Investors" page at http://www.pharmacopeia.com. The replays will be available for two weeks.
Pharmacopeia is a clinical development stage biopharmaceutical company
dedicated to discovering and developing novel small molecule therapeutics
to address significant medical needs. The company has a broad portfolio of
clinical and preclinical candidates under development internally or with
partners including seven clinical compounds in Phase 2 or Phase 1
development addressing hypertension, diabetic nephropathy, muscle wasting,
inflammation and respiratory disease. The company is leveraging its fully
Copyright©2007 PR Newswire.
All rights reserved